| 查看: 497 | 回复: 1 | ||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | ||
yaping221木虫 (正式写手)
|
[求助]
脂组学类翻译，谢谢！
|
|
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. |
回复此楼» 猜你喜欢
到新单位后，换了新的研究方向，没有团队，持续积累2区以上论文，能申请到面上吗
已经有13人回复
-
博士申请都是内定的吗？
已经有6人回复
-
之前让一硕士生水了7个发明专利，现在这7个获批发明专利的维护费可从哪儿支出哈？
已经有5人回复
-
博士读完未来一定会好吗
已经有29人回复
-
投稿精细化工
已经有4人回复
-
高职单位投计算机相关的北核或SCI四区期刊推荐，求支招！
已经有4人回复
-
导师想让我从独立一作变成了共一第一
已经有9人回复
-
读博
已经有4人回复
-
心脉受损
已经有5人回复
-
Springer期刊投稿求助
已经有4人回复
genhunter
至尊木虫 (著名写手)
- 翻译EPI: 387
- 应助: 259 (大学生)
- 金币: 9757.4
- 散金: 10
- 红花: 60
- 帖子: 2484
- 在线: 1793小时
- 虫号: 2558361
- 注册: 2013-07-22
- 专业: 肿瘤化学药物治疗
【答案】应助回帖
★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★ ★
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
yaping221: 金币+30, 翻译EPI+1 2016-03-06 09:30:31
|
In future personalized medicine enabled by lipidomics and metabolomic may expedite the mission of the right patients receiving the right drug at the right time and dose. Recently more potent drugs including monoclonal antibodies able to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) and inflammatory pathways have been developed to improve current CAD care. 在未来基于脂类组学和代谢组学的个性化医学可以加快对合适病人的选择，以及选对药物，用药时间和剂量的决定。最近, 更为有效的药物，包括能抑制前蛋白转化酶枯草溶菌素 9型（PCSK9）和炎症通路的单克隆抗体已经开发，用于改善冠状动脉疾病的治疗。 However, these novel targeted treatments seem to be at present too expensive to be widely used among all CAD patients. Thus, sensitive biomarkers are needed for identification of patients most suitable for novel innovative treatments and the metabolomic and lipidomic biomarker candidates, in particular the ceramides, hold the potential to become clinically useful companion diagnostics of the future. 然而，在目前看来，这些新的靶向治疗比较昂贵，难以在所有冠状动脉疾病患者中广泛应用。因此，需要用灵敏的生物标志物去确定最合适新疗法以代谢和脂类生物标志物测定的的候选患者, 尤其是神经酰胺，未来有可能成为临床上有用的辅助诊断。 |
2楼2016-03-05 15:38:03